[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"brain-ischemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:brain-ischemia":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,45,83,114,143,184,215,241,265,288,312,339],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100640279","a-cluster-randomized-trial-of-a-telemedicine-enabled-integrated-care-model-for-stroke-prevention-and-management-in-rural-elderly-adults-in-china-100640279",false,"NCT07628283","A Cluster Randomized Trial of a Telemedicine-Enabled Integrated Care Model for Stroke Prevention and Management in Rural Elderly Adults in China","A Prospective, Open-Label, Cluster Randomized Controlled Trial to Evaluate the Efficacy of a Rural Doctor-Led, Telemedicine-Supported Integrated Care Model for Reducing Cardiovascular and Cerebrovascular Events in Elderly Adults at High Risk of Stroke in China","Inclusion Criteria:\n\n1. Aged 65 years or older\n2. Rural residents with household registration or long-term residence (≥6 months\u002Fyear) in the study area\n3. High risk of stroke as defined by the National Health Commission's \"8+2\" stroke risk screening tool: ≥3 risk factors OR history of stroke\u002FTIA\n4. Willing to receive long-term health management from the assigned village clinic\n5. Written informed consent provided by the participant or their legal representative\n\nExclusion Criteria:\n\n1. Severe dementia or psychiatric disorder that prevents completion of study follow-up and assessments\n2. Life expectancy less than 1 year (e.g., advanced malignancy, end-stage renal disease)\n3. Currently participating in another interventional clinical trial","ALL","65 Years",{"count":19,"type":20},2510,"ESTIMATED","INTERVENTIONAL",[23],"NA","This cluster randomized controlled trial aims to evaluate the effectiveness of a novel telemedicine-enabled integrated care model led by rural doctors in reducing cardiovascular and cerebrovascular events among elderly adults (≥65 years) at high risk of stroke in rural China. A total of 39 village clinics will be randomized to either the intervention group (digital health platform-supported integrated care) or the control group (enhanced usual care). The primary outcome is a composite of cardiovascular death, stroke, and hospitalization for heart failure or acute coronary syndrome at 36 months.",[26,27,28,29,30,31],"Stroke","Brain Ischemia","Cerebral Hemorrhage","Transient Ischemic Attack","Cardiovascular Diseases","Hypertension","NOT_YET_RECRUITING","2026-05-28",{"date":35,"type":36},"2026-06-05","ACTUAL",{"date":38,"type":20},"2026-06-01",{"date":40,"type":20},"2030-06-30",{"name":42,"class":43},"Jiangsu Province (Suqian) Hospital","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":57,"conditions":58,"keywords":66,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":44},"100633435","head-cooling-in-ischaemic-stroke-patients-undergoing-endovascular-thrombectomy-coolhead-2b-100633435","NCT07526649","Head Cooling in Ischaemic Stroke Patients Undergoing Endovascular Thrombectomy (COOLHEAD-2b)","Head Cooling in Ischaemic Stroke Patients Undergoing Endovascular Thrombectomy: A Phase 2 Randomised Controlled Trial (COOLHEAD-2b)","COOLHEAD-2B","Inclusion Criteria:\n\n* Acute anterior circulation ischaemic stroke planned for endovascular thrombectomy\n* Age ≥18 years\n\nExclusion Criteria:\n\n* Pre-stroke modified Rankin Scale score \\>2\n* Core body temperature \\\u003C35°C at admission\n* Uncontrolled hypertension (≥185\u002F110 mmHg despite treatment in IVT-eligible patients)\n* Known contraindications to hypothermia (e.g., haemodynamic instability, symptomatic bradyarrhythmia, cryoglobulinaemia, sickle cell disease, cold agglutinins)\n* Vasospastic disorders (e.g., Raynaud's phenomenon)\n* Skin lesions preventing secure application of the cooling cap\n* Inability to participate in 90-day follow-up","18 Years",{"count":55,"type":20},182,[23],"COOLHEAD-2b is a multicentre, phase 2, prospective, randomised, controlled, open-label, blinded-endpoint trial evaluating the safety and efficacy of non-invasive convective head cooling as an adjunct to endovascular thrombectomy (EVT) in patients with acute anterior circulation ischaemic stroke. Head cooling is initiated as early as possible, including during inter-hospital transfer, and continued until one hour after reperfusion. The primary efficacy endpoint is final infarct volume at 24 hours.",[26,59,27,60,61,62,63,64,65],"Acute Ischemic Stroke","Ischaemic Stroke","Thrombectomy","Endovascular Procedures","Reperfusion Injury","Cooling","Large Vessel Occlusion",[67,68,69,70,71,72],"Head cooling","Selective brain cooling","Endovascular thrombectomy","Therapeutic hypothermia","Penumbra","Neuroprotection","2026-04-09",{"date":75,"type":36},"2026-04-13",{"date":77,"type":20},"2026-04-10",{"date":79,"type":20},"2029-06-30",{"name":81,"class":82},"Auckland City Hospital","OTHER_GOV",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":90,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":44},"100438662","impact-of-covid-19-vaccines-on-cerebrovascular-health-100438662","NCT04992195","Impact of COVID-19 Vaccines on Cerebrovascular Health","Impact of COVID-19 Vaccines on Cerebrovascular Health - a Population-based Study","Inclusion Criteria:\n\nAll consecutive citizens in the CUHK Brain Health Longitudinal Study cohort who received baseline MRI brain.\n\nExclusion Criteria:\n\n1. Citizens with clinically evident stroke or dementia prior to recruitment; or\n2. Citizens who are unable to provide an informed consent; or\n3. Citizen with contraindications to MRI brain, e.g., non-MRI compatible implants, claustrophobia, etc; or\n4. Citizens who had no baseline MRI brain assessment.",true,{"count":92,"type":20},500,"OBSERVATIONAL","Safe and effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines may reduce the transmission of and achieve population immunity against the COVID-19 pandemic, which accounted for more than 3.75million deaths worldwide. With World Health Organization's (WHO) effort on ensuring equitable access to COVID-19 vaccines, vaccination rate may increase in the near future.\n\nOn the other hand, vaccination hesitancy has emerged as a major hindrance on the global vaccination campaigns in certain areas due to safety concerns, social factors, and public health policies. For instance, a recent survey conducted in Hong Kong showed a low vaccine acceptance rate of 37%. Long-term safety concerns and post-vaccination events relayed by the social media maybe reasons for vaccination hesitancy. Among which, cerebrovascular accidents (CVA) after vaccination were one of the most frequently reported post-vaccination events. These reports ranged from ischemic strokes in elderly patients with multiple cardiovascular co-morbidities, to hemorrhage strokes in otherwise \"young-and-fit\" adults. While many of these events were investigated by the COVID-19 immunization expert committee, an important premise to address the apprehension of CVA after vaccination is the provision of evidence-based information of the impact of COVID-19 vaccines on brain health.\n\nIn this prospective, longitudinal, observational study, we aim to elucidate the relationship between COVID-19 vaccines and cerebrovascular health in healthy citizens in a population-based cohort.",[26,96,97,98,27,99,100,101,102,103],"Stroke, Acute","Stroke, Ischemic","Dementia","Alzheimer Disease","Brain Diseases","Major Adverse Cardiovascular Event","Arterial Thromboembolism","Venous Thromboembolism","RECRUITING","2026-02-21",{"date":107,"type":36},"2026-02-24",{"date":109,"type":36},"2021-07-05",{"date":111,"type":20},"2026-12-31",{"name":113,"class":43},"Chinese University of Hong Kong",{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":90,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":123,"conditions":124,"keywords":130,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":136,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":142},"100331231","cuhk-brain-health-longitudinal-study-100331231","NCT03592563","CUHK Brain Health Longitudinal Study","BHS","Inclusion Criteria:\n\n1. Adult ≥ 18 years of age\n2. Fulfilling criteria for membership in one of these three groups:\n\n   * Red group: established diagnosis of one or more neurological and\u002For psychiatric conditions\n   * Yellow group: high-risk to develop one or more neurological and\u002For psychiatric conditions\n\n     1. family history (first degree relative) one or more neurological and\u002For psychiatric conditions\n     2. examination, imaging or laboratory findings consistent with pre-symptomatic stages of one or more neurological and\u002For psychiatric disorders\n   * Green group: not meeting criteria for Red or Yellow groups, but interested in longitudinal research on maintenance and\u002For improvement of brain health\n3. Subject provides informed consent by signing and dating the written informed consent form\n4. Subject is willing to answer health questionnaires and be followed longitudinally\n\nExclusion Criteria:\n\n* None",{"count":122,"type":20},5000,"The goal of this study is to develop a large longitudinal cohort of individuals diagnosed with or at high risk for brain diseases (both neurological and psychiatric in nature), in order to identify risk factors that contribute to neurological and psychiatric diseases over time. The investigators seek to capture relevant information from medical records, electronically administered questionnaires and follow up phone-based interviews. The investigators expect to eventually have sufficient power from our dataset to examine risk factors for a variety of brain disorders, both individually and in aggregate. Our ultimate goal is to offer scientifically validated ways to preserve and promote brain health by working with our patients' needs and tracking their progress over time.",[97,125,26,96,98,27,100,99,126,127,128,129],"Stroke Syndrome","Health Attitude","Health Knowledge, Attitudes, Practice","Health Personnel Attitude","Healthy Aging",[131,132,133,134,135],"stroke","dementia","Alzheimer disease","Health Brain","Health knowledge",{"date":107,"type":36},{"date":138,"type":36},"2019-07-01",{"date":140,"type":20},"2048-12-31",{"name":113,"class":43},2,{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":151,"targetDuration":152,"studyType":93,"phases":4,"briefSummary":153,"conditions":154,"keywords":166,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":44},"100589453","cardiac-assessment-for-recurrent-stroke-risk-evaluation-in-atrial-fibrillation-100589453","NCT06954610","Cardiac Assessment for Recurrent Stroke Risk Evaluation in Atrial Fibrillation","CARE-AF: Cardiac Assessment for Recurrent Stroke Risk Evaluation in Atrial Fibrillation","CARE-AF","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Written informed consent (by patient, next of kin or legally authorised representative)\n* Permanent, persistent, or paroxysmal AF previously known or diagnosed during the index hospitalisation\n* Acute (≤7 days), symptomatic ischemic stroke\n\nExclusion Criteria:\n\n* Life expectancy \\\u003C1 year according to the opinion of the investigator\n* Patient is unlikely to attend follow-up visits",{"count":92,"type":20},"12 Months","Background\n\nAtrial fibrillation (AF) is the most common cardiac arrhythmia, affecting up to 10% of the elderly. Ischemic stroke is the main complication of AF and cardioembolism is one of the leading causes of ischemic stroke, accounting for approximately one third of cases. Oral anticoagulant therapy (OAC) is a cornerstone in stroke prevention in patients with AF. According to randomized controlled trials of direct oral anticoagulants, a residual risk of ischemic stroke of 1-2% per year for so-called \"breakthrough stroke\" remains, despite adequate intake of OAC. The majority (\\>70%) of these breakthrough strokes are cardioembolic in nature and only a minority are related to medication issues (e.g. non-compliance) or other, non-AF related etiologies. Stroke recurrence risk after such a breakthrough stroke markedly increases to 8-9% per year indicating a particularly high-risk situation. Why OAC fails in certain patients, but not in others remains as poorly understood, as does the reason why the subsequent risk of stroke is so high.\n\nCurrent risk stratification tools, such as the widely used CHA2DS2-VA(Sc)-score, fail to predict stroke risk in such a high-risk cohort, as they were intended to guide the initiation of OAC in low to moderate risk patients. In light of new therapeutic strategies currently being investigated, such as percutaneous left atrial appendage occlusion in patients with breakthrough strokes (ELAPSE - NCT05976685) or in AF-patients deemed high-risk (LAAOS IV - NCT05963698), improved risk stratification and characterization of high-risk AF patients is highly warranted.\n\nSeveral clinical factors, such as those reflected in the CHA2DS2-VA(Sc)-score, and especially a high AF-burden are associated with increased risk of cardioembolic stroke. Several cardiac serum biomarkers are thought to be surrogates not only of cardiac function, but also of cardioembolic risk. Reflecting ventricular and atrial wall tension, myocardial injury, oxidative stress and thrombogenicity, elevated NT-proBNP, MR-proANP, high-sensitive Troponin T and D-Dimers have all been associated with cardioembolic stroke in different AF and non-AF populations. As the main location of thrombus formation, the left atrium (LA) and more specifically its appendage (LAA) are of particular interest in the pathogenesis of cardioembolism. Pronounced LA-enlargement, compared to a normal-sized LA, correlates with an increased risk of cardioembolism in AF-patients. As over 80% of thrombi form within the LAA, several LAA-characteristics, such as slower LAA-flow velocity and larger LAA-orifice area have also been demonstrated to be associated with higher stroke risk. Although there is data on each one of these factors, they have only been investigated in low to moderate risk populations, such as AF-patients without prior stroke, OAC-naïve patients, or even within the general population as a whole. Their role in high-risk AF-patients and in breakthrough stroke is unknown.\n\nHypothesis\n\nThe investigators hypothesize that specific clinical factors, serum cardiac biomarkers and markers of LA- and LAA-morphology and function are associated with breakthrough stroke \u002F OAC-failure and may improve risk stratification.\n\nMethods\n\nCARE-AF is a single-center, prospective cohort study conducted at the Stroke Center of the Inselspital, University Hospital Bern, Switzerland. Patients with an index ischemic stroke and AF (breakthrough and non-breakthrough cases) will be enrolled. The investigators will collect clinical data, serum cardiac biomarkers and echocardiographic indices of the LA and LAA. All patients will receive standardized annual follow-ups until the end of the study, defined as 12 months after the inclusion of the last participant. The primary endpoint is ischemic stroke or systemic embolism during follow-up. First, in a cross-sectional design, the study will assess the association between serum cardiac biomarkers and echocardiographic indices among patients with breakthrough vs. non-breakthrough stroke as index event, applying multivariate regression models. Second, the investigators will perform a longitudinal analysis assessing the association between the variables mentioned above and breakthrough stroke as index event with the primary endpoint, using multivariate Cox regression models. The study aims to enroll a minimum of 500 patients, which provides sufficient power to detect a clinically meaningful adjusted hazard ratio for recurrent stroke of 1.5 with 80% power at an alpha level of 5%.\n\nConclusion\n\nThe results of this project will enhance understanding of the role of specific clinical factors, cardiac serum biomarkers and echocardiographic indices in the residual risk of stroke in patients with AF on anticoagulation therapy. They may improve current risk stratification and have the potential to help guide therapeutic decisions in high-risk situations considering evolving therapeutic possibilities.",[155,156,157,100,158,159,160,161,162,27,163,26,164,165],"Ischemic Stroke","Atrial Fibrillation","Cerebrovascular Disorders","Central Nervous System Diseases","Vascular Diseases","Arrhythmias, Cardiac","Heart Diseases","Brain Infarction","Infarction Cerebral","Cardioembolic Stroke","Ischemia",[167,168,169,170,171,172,173,174],"Ischemic stroke","Direct oral anticoagulation","Anticoagulation","Breakthrough stroke","Risk stratification","Atrial fibrillation","Anticoagulant therapy","Direct oral anticoagulant","2025-11-17",{"date":177,"type":36},"2025-11-20",{"date":179,"type":36},"2025-11-04",{"date":181,"type":20},"2028-06-30",{"name":183,"class":43},"Insel Gruppe AG, University Hospital Bern",{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":191,"enrollmentInfo":192,"targetDuration":4,"studyType":21,"phases":194,"briefSummary":195,"conditions":196,"keywords":205,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":211,"leadSponsor":213,"locationsCount":44},"100606900","anesthesia-techniques-neuroprotection-and-surgical-field-in-fess-under-controlled-hypotension-100606900","NCT07181564","Anesthesia Techniques, Neuroprotection and Surgical Field in FESS Under Controlled Hypotension","FUNCTIONAL ENDOSCOPIC NASAL AND SINUS SURGERY AND ANESTHESIA: Study of Hemodynamic Parameters During General Anesthesia Compared to the Surgical Field, as Well as Assessment of Cerebral Ischemia Intraoperatively by Measurement of S100B Protein and Specific Neuronal Enolase (NSE).","Inclusion Criteria :\n\nAdult patients (≥18 years old). Scheduled for F.E.S.S (Functional endoscopic sinus surgery ) under general anesthesia.\n\nAble to provide informed consent\n\nExclusion Criteria:\n\nEmergency surgery. ASA physical status IV-V. Severe hepatic or renal dysfunction. Known allergy or contraindication to study drugs. Pregnant or lactating women. unable to provide informed consent\n\nPatients unwilling or unable to provide consent.","90 Years",{"count":193,"type":20},150,[23],"This prospective, randomized controlled trial investigates the effect of four different anesthetic maintenance techniques on surgical field conditions, hemodynamic stability, and neuroprotection during functional endoscopic sinus surgery (FESS) performed under controlled hypotension. Patients are randomly assigned to receive either total intravenous anesthesia with propofol-remifentanil, propofol-remifentanil with adjunct ketamine and magnesium, sevoflurane-remifentanil, or sevoflurane-remifentanil with adjunct ketamine and magnesium. Primary outcomes include serum biomarkers of neuronal injury (S100B and neuron-specific enolase, NSE) measured perioperatively, as well as surgical field visibility and intraoperative bleeding scores. Secondary outcomes include recovery profile and postoperative pain.",[197,198,199,200,201,27,202,203,204],"Magnesium Sulfate","Remifentanil","S 100beta","S100 Beta Protein, Human","Neuron-Specific Enolase","Sevoflurane Anaesthesia","Propofol\u002FRemifentanil","Ketamine",[206],"\"Anesthesia\", \"Controlled Hypotension\", \"FESS\", \"S100B\", \"Neuron-Specific Enolase\"","2025-09-11",{"date":209,"type":36},"2025-09-18",{"date":207,"type":36},{"date":212,"type":20},"2026-03-20",{"name":214,"class":43},"University General Hospital of Patras",{"id":216,"slug":217,"hasResults":11,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":221,"eligibilityCriteria":222,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":223,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":225,"conditions":226,"keywords":228,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":44},"100525407","precision-medicine-in-stroke-evolution-of-plasma-brain-derived-tau-in-acute-stroke-100525407","NCT06121336","PRecisiOn Medicine In StrokE: Evolution of Plasma Brain-Derived Tau in Acute Stroke","PRecisiOn Medicine In StrokE Study on the Evolution of Plasma Brain-Derived Tau in 100 Patients With Acute Ischemic Stroke","PROMISE-BD-100","Inclusion Criteria:\n\n* clinical diagnosis of acute ischemic stroke\n* presentation within 9 hours of symptom onset\n* large- or medium-vessel occlusion (i.e. an occlusion of the ICA, MCA \\[segments M1-M4\\], ACA \\[segments A1-A3\\], basilar artery, or PCA \\[segments P1 to P3\\]) confirmed by CT or MRI angiography\n* at least 18 years of age\n* written informed consent\n\nExclusion Criteria:\n\n* CT or MRI showing intracranial hemorrhage upon admission\n* A history of ischemic stroke, subarachnoid hemorrhage, intracerebral hemorrhage, subdural hematoma, epidural hematoma, CNS tumor, meningitis, or encephalitis within the last three months\n* severe renal dysfunction (eGFR \\\u003C 30ml\u002Fmin\u002F1.73m2)\n* dementia\n* pre-stroke disability defined as a premorbid modified Rankin Scale score \\> 1",{"count":224,"type":20},100,"The investigators recently identified Brain-derived tau (BD-tau) as a sensitive blood-based biomarker for brain injury in acute ischemic stroke: in patients with acute ischemic stroke, plasma BD-tau was associated with imaging-based metrics of brain injury upon admission, increased within the first 24 hours in correlation with infarct progression, and at 24 hours was superior to final infarct volume in predicting 90-day functional outcome. While informing on the relation of BD-tau with imaging-based metrics of brain injury, this cross-sectional study was restricted to BD-tau assessments upon admission and at day 2 and could not inform on key characteristics of the evolution of plasma BD-tau, including when exactly it starts to rise, how long it continues to rise, and how it is determined by infarct characteristics as well as comorbidities. Here, the investigators aim to assess plasma BD-tau every hour from admission to 48 hours after onset to evaluate the hypothesis that BD-tau rises immediately after onset and plateaus between three and 48 hours after onset.",[26,96,97,157,100,158,27,227],"Nervous System Diseases",[26,229,230,231],"Brain injury","Biomarker","Pathophysiology","2025-09-02",{"date":234,"type":36},"2025-09-04",{"date":236,"type":36},"2023-03-01",{"date":238,"type":20},"2026-09-30",{"name":240,"class":43},"Ludwig-Maximilians - University of Munich",{"id":242,"slug":243,"hasResults":11,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":4,"eligibilityCriteria":247,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":248,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":250,"conditions":251,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":44},"100598281","prognostic-value-of-isolated-and-combined-score-aspects-in-acute-ischemic-stroke-100598281","NCT07069452","Prognostic Value of Isolated and Combined Score Aspects in Acute Ischemic Stroke","TARGET-ASPECT (Prognostic Value of Isolated and Combined Score Aspects in Acute Ischemic Stroke)","Inclusion Criteria :\n\n* Patients aged 18 years or older\n* Confirmed acute ischemic stroke on imaging\n* Treated with both thrombolysis and thrombectomy\n* Clinical follow-up data available at 90 days (mRS score)\n\nExclusion Criteria :\n\n* Primary hemorrhagic stroke\n* Early death or loss to follow-up without evaluation\n* Poor-quality imaging that cannot be analyzed",{"count":249,"type":20},152,"This study, called TARGET-ASPECT, looks at patients who had a type of stroke called acute ischemic stroke and were treated with clot-busting medicine and a procedure to remove the clot. Even with these treatments, about half of patients don't fully recover. The study aims to see if certain brain imaging scores, especially when combined, can better predict how well patients will recover 90 days after their stroke and if their blood vessels reopen successfully. The study will include 152 patients and last about 9 months. The goal is to find easy and reliable tools that doctors can use to make better treatment decisions.",[97,61,252,27,253,254,255],"Thrombolytic Therapy","Prognosis","Magnetic Resonance Imaging","Outcome Assessment (Health Care)","2025-07-15",{"date":258,"type":36},"2025-07-16",{"date":260,"type":36},"2025-04-15",{"date":262,"type":20},"2026-01-15",{"name":264,"class":43},"Centre Hospitalier de Gonesse",{"id":266,"slug":267,"hasResults":11,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":271,"eligibilityCriteria":272,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":273,"enrollmentInfo":274,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":276,"conditions":277,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":44},"100583219","evaluation-of-patients-affected-by-traumatic-and-hypoxic-ischemic-brain-injury-100583219","NCT06873477","Evaluation of Patients Affected by Traumatic and Hypoxic-ischemic Brain Injury","Clinical and Epidemiological Evaluation of Patients Affected by Traumatic and Hypoxic-ischemic Brain Injury","PETRA","Inclusion Criteria:\n\n* Patients aged 0-20 years with brain damage due to severe traumatic brain injury or perinatal asphyxia evaluated at the Pediatric Emergency Department\n* Informed consent signed by the parents, the adult patient, or the legal guardian\u002Frepresentative.\n* Adult patients with psycho-cognitive impairments that affect their ability to provide consent, with prior acquisition of informed consent from the guardian\u002Flegal representative.\n\nExclusion Criteria:\n\n* Refusal to sign the informed consent\n* Patients with congenital malformations or genetic syndromes\n* Patients with neuromuscular diseases\n* Patients with encephalopathies of etiology other than severe head trauma or asphyxia\n* Patients with hemodynamically significant congenital heart diseases","20 Years",{"count":275,"type":20},50,"According to the World Health Organization, perinatal asphyxia is the leading cause of severe neurological disabilities and the second leading cause of neonatal death among term infants, with an incidence of 3.94-5.12 per 1,000 live births. Perinatal asphyxia leads to neonatal hypoxic-ischemic encephalopathy, which remains a common cause of neonatal death and long-term disabilities, affecting 1.5-3 per 1,000 live births in developed countries and up to 26 per 1,000 live births in developing countries. This condition is characterized by altered levels of consciousness or manifests with seizures, often associated with difficulties in initiating and maintaining breathing, as well as depression of tone and reflexes. Currently, therapeutic hypothermia is the standard treatment for neonates with moderate to severe hypoxic-ischemic encephalopathy; however, it does not provide complete neuroprotection and is only partially effective. Therefore, new treatments with good therapeutic windows are urgently needed to ensure the best possible preservation of neurological tissue for patients exposed to hypoxic-ischemic insult. Traumatic brain injury is a common cause of morbidity and mortality among children and young adults in developed countries. The incidence of traumatic brain injury has increased in recent years, yet the prognosis for these patients has not substantially changed. In recent studies the key intermediary role of the immune system and neuroinflammation has been proposed to explain the pathophysiology of traumatic brain injury, both in the acute phase and in the long term. Indeed, neuroinflammatory processes can persist for several months, contributing to chronic alterations and accelerating brain aging in patients with post-traumatic brain injury. Currently, therapies that have shown promising results in patients with post-traumatic brain injuries are unfortunately still limited, especially in the context of severe traumatic brain injury. Thus, there is an urgent need for new treatments with a broader therapeutic window that can counteract early and chronic pathophysiological events.",[278,27],"Brain Injuries","2025-03-06",{"date":281,"type":36},"2025-03-12",{"date":283,"type":36},"2025-01-15",{"date":285,"type":20},"2027-07-31",{"name":287,"class":43},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":289,"slug":290,"hasResults":11,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":4,"eligibilityCriteria":294,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":295,"enrollmentInfo":296,"targetDuration":4,"studyType":21,"phases":297,"briefSummary":298,"conditions":299,"keywords":300,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":310,"locationsCount":44},"100437815","informative-of-surface-electromyography-and-prognostic-factors-in-assessing-the-recovery-of-balance-and-gait-after-stroke-100437815","NCT04981184","Informative of Surface Electromyography and Prognostic Factors in Assessing the Recovery of Balance and Gait After Stroke","Informative of Surface Electromyography and Determination of Prognostic Factors in Assessing the Probability of Recovery of Balance and Gait Parameters in Patients With Ischemic Stroke on Acute Rehabilitation","Inclusion Criteria:\n\n* Cerebral infarction for the first time;\n* Age from 18 to 89 years old;\n* Muscle strength according to the Oxford scale is 3-5 points;\n* Able to walk without the help of others;\n* Is able to communicate and understand instructions properly;\n* Agrees to participate in the study (voluntary, explicit, informed written consent to participate).\n\nExclusion Criteria:\n\n* Muscle strength according to the Oxford scale is 0-2 points;\n* Unable to walk without the help of others;\n* Sensorimotor aphasia or other perceptual disorders;\n* Do not sign the informed consent.","89 Years",{"count":224,"type":20},[23],"The aim of the biomedical research is to determine the informativeness and prognostic factors of surface electromyography by assessing the probability of recovery of balance and gait parameters in the second stage of rehabilitation of persons with cerebral infarction.",[27],[301,302,303,167],"Surface Electromyography","Gait","Balance","2024-10-16",{"date":306,"type":36},"2024-10-17",{"date":308,"type":36},"2019-07-22",{"date":238,"type":20},{"name":311,"class":43},"Lithuanian University of Health Sciences",{"id":313,"slug":314,"hasResults":11,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":318,"eligibilityCriteria":319,"healthyVolunteers":11,"sex":16,"minAge":320,"maxAge":4,"enrollmentInfo":321,"targetDuration":4,"studyType":21,"phases":323,"briefSummary":324,"conditions":325,"keywords":328,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":44},"100547579","electrocorticographic-monitoring-of-brain-retraction-injury-embri-100547579","NCT06409806","Electrocorticographic Monitoring of Brain Retraction Injury (EMBRI)","Electrocorticography As a Neurophysiological Marker for Intraoperative Monitoring for Brain Retraction: an IDEAL Stage 1 Study","EMBRI","Inclusion Criteria:\n\n* Patients aged 16 or older undergoing intracranial surgery where it is anticipated fixed brain retraction will be used.\n\nExclusion Criteria:\n\n* Patients without capacity to give consent at time of recruitment","16 Years",{"count":322,"type":20},6,[23],"A single centre IDEAL Stage 1 feasibility study using novel electrophysiological recording techniques in adult participants undergoing neurosurgery. This is a first in human study, building upon previous preclinical mice experiments.\n\nParticipants will undergo their planned neurosurgical procedure as normal. In addition to their standard treatment neurophysiological monitoring including an electrocorticography electrode placed on the brain deep to the retractor will be used to monitor for signs of brain retraction injury.",[326,327,27],"Brain Injury","Neurosurgery",[329],"Brain retraction","2024-09-17",{"date":332,"type":36},"2024-09-19",{"date":334,"type":36},"2022-08-01",{"date":336,"type":20},"2026-03-01",{"name":338,"class":43},"University College, London",{"id":340,"slug":341,"hasResults":11,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":345,"eligibilityCriteria":346,"healthyVolunteers":11,"sex":16,"minAge":347,"maxAge":4,"enrollmentInfo":348,"targetDuration":350,"studyType":93,"phases":4,"briefSummary":351,"conditions":352,"keywords":4,"overallStatus":104,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":44},"100278144","population-based-brest-stroke-registry-100278144","NCT02900521","Population-based Brest Stroke Registry","The Brest Registry of Stroke","BREST","Inclusion Criteria:\n\n* Diagnostic validated for one of the following pathologies:\n* Ischemic stroke,\n* Non-traumatic intracranial hematoma\n* Cerebral venous thrombosis Diagnostic after December 31, 2007 Age \\> 15 years on the date of the diagnostic Patient domiciled at the time of the diagnostic in one of the 79 communes defined beforehand\n\nExclusion Criteria:\n\n* Age ≤ 15 years\n* Validated diagnosis (see below, § 4.2.2) of aneurysmal subarachnoid hemorrhage cerebrovascular\n* Diagnosis made before 1 January 2008\n* Unconfirmed diagnosis\n* Patient domiciled outside the previously defined area of residence","15 Years",{"count":349,"type":20},15000,"10 Years","The registry is the main objective exhaustive list of cases validated stroke brain on a geographical area defined to calculate an incidence.",[353,354,26,27,355,155,356,157,357],"Cerebral (CVAs)","Ischemic Cerebrovascular Accident","Brain Hemorrhage","Hemorrhagic Stroke","Transient Ischemic Attack (TIA)","2023-05-25",{"date":360,"type":36},"2023-05-26",{"date":362,"type":36},"2008-01",{"date":364,"type":20},"2026-12",{"name":366,"class":43},"University Hospital, Brest"]